Home  »  Finance   »  Gossamer Bio Inc (NASDAQ: GOSS): Should Value Hunt...

Gossamer Bio Inc (NASDAQ: GOSS): Should Value Hunters Buy Stock?

Gossamer Bio Inc (NASDAQ:GOSS) price closed higher on Monday, February 12, jumping 1.15% above its previous close.

A look at the daily price movement shows that the last close reads $0.87. The company’s 5Y monthly beta was ticking 1.57. Taking into account the 52-week price action we note that the stock hit a 52-week high of $2.53 and 52-week low of $0.45. The stock subtracted -5.10% on its value in the past month.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Gossamer Bio Inc, which has a market valuation of $198.36 million, is expected to release its quarterly earnings report Mar 15, 2024 – Mar 19, 2024. Analysts tracking GOSS have forecast the quarterly EPS to shrink by -0.21 per share this quarter, while the same analysts predict the annual EPS to hit -$1.25 for the year 2024 and up to -$0.79 for 2024. In this case, analysts estimate an annual EPS growth of 53.90% for the year and 36.80% for the next year.

Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give GOSS a short term outlook of Hold on average. Looking at the stock’s medium term indicators we note that it is averaging as a 50% Sell, while an average of long term indicators are currently assigning the stock as 50% Sell.

The overview shows that GOSS’s price is at present 2.55% off the SMA20 and -2.92% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 52.13, with weekly volatility standing at 6.83%. The indicator jumps to 9.70% when calculated based on the past 30 days. Gossamer Bio Inc (NASDAQ:GOSS)’s beta value is holding at 1.57, while the average true range (ATR) indicator is currently reading 0.08.

Turning out attention to how the Gossamer Bio Inc stock has performed in comparison to its peers in the industry, here’s what we find: GOSS’s stock is 1.15% on the day and -61.57% in the past 12 months, while Johnson & Johnson (JNJ) traded 0.70%% in the last session and was positioned -3.01% down on its price 12 months ago. Turning out attention to how the Gossamer Bio Inc stock has performed in comparison to its peers in the industry, here’s what we find: GOSS’s stock is 1.15% on the day and -61.57% in the past 12 months, while Johnson & Johnson (JNJ) traded 0.70%% in the last session and was positioned -3.01% down on its price 12 months ago. Another comparison is with Merck & Co. Inc. (MRK) whose stock price was down -0.09%% in the last trading session, and has flourished 14.41% over the past year. Also, AbbVie Inc. (ABBV) showed down trend of -0.58%% while its price kept floating at 12.58% over the past year.

An analysis of the Gossamer Bio Inc (NASDAQ:GOSS) stock in terms of its daily trading volume indicates that the 3-month average is 2.06. However, this figure increases on the past 10-day timeline to an average of 0.51 million.

Current records show that the company has 225.41M in outstanding shares. The insiders’ percentage holdings are 19.13% of outstanding shares while the percentage share held by institutions stands at 82.59%. The stats also highlight that short interest as of Jan 31, 2024, stood at 16.72 million shares, which puts the short ratio at the time at 28.45. From this we can glean that short interest is 7.42% of company’s current outstanding shares. Notably, we see that shares short in January fall slightly given the previous month’s figure stood at 17.56 million. But the -3.56% downside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.